A Randomized Phase 2 Study of Human Anti-PDGFR-alpha Monoclonal Antibody IMC-3G3 Plus Mitoxantrone Plus Prednisone or Mitoxantrone Plus Prednisone in Metastatic Castration-Refractory Prostate Cancer Following Disease Progression or Intolerance on Docetaxel-based Chemotherapy.

Trial Profile

A Randomized Phase 2 Study of Human Anti-PDGFR-alpha Monoclonal Antibody IMC-3G3 Plus Mitoxantrone Plus Prednisone or Mitoxantrone Plus Prednisone in Metastatic Castration-Refractory Prostate Cancer Following Disease Progression or Intolerance on Docetaxel-based Chemotherapy.

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Aug 2014

At a glance

  • Drugs Olaratumab (Primary) ; Mitoxantrone; Prednisone
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Sponsors Eli Lilly; ImClone Systems
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 22 Jan 2014 According to the ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
    • 17 Apr 2013 Planned number of patients changed from 120 to 123 as reported by German Clinical Trials Register.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top